STATCenter·
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.
Read at STAT →
Health · 1 sources covering this
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/5df8149399216dead84ee135d6b54357735fed6e" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent"></iframe>
